Celcuity (CELC) Stock
Cancer diagnostics company matching patients to treatment options. Here's the price, business snapshot, and what's worth knowing about Celcuity in October 2026.
Celcuity Inc (CELC) is a clinical-stage diagnostics company focused on precision oncology. The business works on identifying and validating biomarkers and developing assays that aim to help match cancer patients with targeted therapies or clinical trial options. Investors typically watch clinical data readouts, regulatory progress and any partnerships with pharmaceutical companies, as these milestones can influence future commercial potential. With a market capitalisation around $2.8 billion, Celcuity is relatively small and may exhibit significant share-price volatility. As with any early-stage healthcare company, risks include clinical setbacks, regulatory hurdles and funding needs. This summary is for educational purposes only and not personalised investment advice; values can rise or fall and past performance is not a guide to future results. Consider seeking independent financial or medical advice to assess suitability for your circumstances.
Celcuity (CELC) Stock Forecast
Analyst price target, next 12 months
$107.71
+49.4% vs today's $72.10
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Celcuity have a consensus 12-month target of $107.71, above the current price of $72.10.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Celcuity's stock, predicting significant potential for price growth.
Financial Health
Celcuity Inc. is producing a strong cash flow per share, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Precision oncology focus
Works on biomarkers and assays to better match patients with therapies; scientific breakthroughs could drive upside, though clinical success is uncertain.
Partnership potential
Collaborations with pharma could accelerate development and commercialisation, but such deals typically depend on positive trial and regulatory outcomes.
Early-stage risks
Clinical, regulatory and funding risks can cause significant share-price swings; this profile may suit investors prepared for high volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.